EUVIMEDEUVIMED entdecken
Open Access

Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas

Nicholas S Cho iD, Viên Lam Le iD, Ashley Teraishi iD, Vicki Liu, Francesco Sanvito iD, Donatello Telesca, Masanori Nakajo, Chencai Wang, Sonoko Oshima iD, Blaine S C Eldred, Jingwen Yao, Phioanh L Nghiemphu iD und 4 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Nicholas S Cho und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Isocitrate Dehydrogenase, Mutation, Glioma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, Department of Defense Congressionally Directed Medical Research Programs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study explored MRI characteristics at the time of tumor progression to study pathologically confirmed MT in IDHm 1p/19q-intact astrocytomas (IDHm-A) and IDHm 1p/19q-co-deleted oligodendrogliomas (IDHm-O).

Methods

N = 64 patients with initial pathological grade 2 IDH-mutant glioma diagnosis who underwent repeated tissue sampling and were classified as pathologically confirmed MT (n = 35) or non-MT (n = 29) with available presurgical anatomical (n = 64), diffusion-weighted (n = 61), and dynamic susceptibility contrast perfusion MRI (n = 53) were retrospectively studied. Measurable contrast enhancement (> 1000 mm3), tumor volume, tumor growth rate, sphericity, median apparent diffusion coefficient (ADC), and normalized relative cerebral blood volume (nrCBV) were compared between MT vs non-MT IDHm-A and IDHm-O.

Results

81% of contrast-enhancing IDHm-A and 100% of contrast-enhancing IDHm-O demonstrated MT, while 41% of IDHm-A and 62% IDHm-O exhibited both nonenhancing tumor progression and MT. Tumor volumes were significantly larger in patients with MT compared to non-MT groups for IDHm-A (P = .02) and IDHm-O (P = .04). T2/FLAIR tumor volume growth rate was significantly higher (P = .003), nrCBV was significantly higher (P = .002), and ADC trended lower (P = .06) in MT vs non-MT IDHm-A. There were no significant differences in growth rate, ADC, nrCBV, or sphericity when comparing MT vs non-MT IDHm-O (P > .05).

Conclusions

Many MT IDHm gliomas remain nonenhancing. Growth rate, diffusion, and perfusion MRI show differences between MT and non-MT in IDHm-A but not IDHm-O, which may reflect the different tumor biology of these IDHm molecular subtypes and their need for separate imaging biomarkers. Tumor volumes can help determine MT for both IDHm-A and IDHm-O.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsIsocitrate DehydrogenaseMutationGliomaCell Transformation, NeoplasticMagnetic Resonance ImagingHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedDiffusion Magnetic Resonance ImagingYoung AdultPrognosisFollow-Up StudiesDisease Progression

Stichwörter der Autor:innen

GliomaIDH-mutant astrocytomaIDH-mutant oligodendrogliomaMRImalignant transformation

Substanzen

Isocitrate Dehydrogenase

Autor:innen und Institutionen

  • Medical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, USA.
  • Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.
  • Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

ORCID-Profile: Nicholas S Cho, Viên Lam Le, Ashley Teraishi, Francesco Sanvito, Sonoko Oshima, Phioanh L Nghiemphu, Noriko Salamon, Albert Lai, Benjamin M Ellingson

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • Department of Defense Congressionally Directed Medical Research Programs
  • NIH HHS
  • National Institutes of Health
  • National Institute of General Medical Sciences
  • National Cancer Institute

Zitieren

APA

Cho, N. S., Le, V. L., Teraishi, A., Liu, V., Sanvito, F., Telesca, D., Nakajo, M., Wang, C., Oshima, S., Eldred, B. S. C., Yao, J., Nghiemphu, P. L., Salamon, N., Cloughesy, T. F., Lai, A., & Ellingson, B. M. (2025). Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf171

Vancouver

Cho NS, Le VL, Teraishi A, Liu V, Sanvito F, Telesca D, et al. Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf171

BibTeX
@article{Cho2025,
  author = {Cho, Nicholas S and Le, Viên Lam and Teraishi, Ashley and Liu, Vicki and Sanvito, Francesco and Telesca, Donatello and Nakajo, Masanori and Wang, Chencai and Oshima, Sonoko and Eldred, Blaine S C and Yao, Jingwen and Nghiemphu, Phioanh L and Salamon, Noriko and Cloughesy, Timothy F and Lai, Albert and Ellingson, Benjamin M},
  title = {Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf171}
}
Kostenlos starten →